-
Panelists address cost, quality, and disparities in diabetes care
Osagie Ebekozien, MD, MPH, CPQH, and other experts outlined the ramifications of existing disparities in diabetes care, the importance of person-centered care, and the need for collaboration to improve patient outcomes.
-
Continuous glucose monitors, insulin pens, other technology transform diabetes care
New options for collecting timely, comprehensive blood glucose data facilitates real-time tracking of the effects of food, nutrition, and medication. Caitlin Nass, MSN, CRNP, and other panelists explain what real-world changes clinicians and patients living with diabetes experience.
-
Experts debate whether immune or beta cells precipitate progression of type 1 diabetes
Jamie L. Felton, MD, argued that immune cells precipitate disease advancement, while Edward Phelps, PhD, made the case that beta cells are a more influential factor.
-
Symposium outlines patient and economic perspectives of navigating pediatric type 1 diabetes
Amanda Twigg, MD, discussed being a parent with the disease whose child also has the disease and deciding whether to participate in clinical prevention trials.
-
Debate weighs efficacy of AI for personalized nutrition planning
As with many rapid advancements in artificial intelligence in health care, some question whether the technology is ready for utilization in a real-world environment. Samantha Kleinberg, PhD, and Holly Nicastro, PhD, presented two sides of the debate.
-
Specialists highlight the highs and lows of cannabis use among patients with diabetes
Restrictive guidelines have made studying the effects of cannabis challenging for investigators. An Ask the Expert session analyzed the limited literature available. Halis K. Akturk, MD, discussed distinguishing symptoms caused by cannabis use versus those directly related to patients’ diabetes.
-
Session addresses disparities in access to antiobesity medications
Pharmacoequity describes the goal of ensuring that everyone—regardless of race, ethnicity, or socioeconomic status—has affordable access to life-saving therapies. Panelists including Kristina H. Lewis, MD, MPH, SM, discussed the challenges to attaining pharmacoequity, such as overcoming provider bias.
-
Investigator presents detrimental effects of weight cycling
Weight loss improves diabetes risk factors associated with obesity, yet many patients struggle to maintain weight loss over time. Approximately one in five men and one in four women may experience weight cycling. Heather Caslin, PhD, shared key findings on the harmful effects of these fluctuations.
-
ATTEMPT trial shows kidney, glycemic benefits for SGLT2 inhibitor in adolescents with type 1 diabetes
Jennifer L. Sherr, MD, PhD, and other investigators shared the latest data from the first randomized controlled trial of a sodium-glucose cotransporter protein-2 (SGLT2) inhibitor in adolescents with type 1 diabetes at the 84th Scientific Sessions.
-
TIGHT investigators share lessons learned from evaluating inpatient CGM
Despite a lack of improvement in glycemic management in TIGHT, Guillermo Umpierrez, MD, CDCES, MACP, FACE, said he was optimistic about the future of determining hypoglycemia and hyperglycemia for hospitalized patients with diabetes.